早期类风湿关节炎达标治疗中疲劳的预测因素与治疗反应
该研究基于ARCTIC试验数据,纳入205例早期类风湿关节炎(RA)患者,随访24个月,评估达标治疗期间疲劳与疾病活动度的关联及24个月疲劳的基线预测因素。结果显示疲劳患病率从基线69%降至24个月38%,基线肿胀关节数少、能量多普勒超声评分低及患者总体评估(PGA)高是24个月临床相关疲劳的预测因素,6个月未达标与24个月疲劳风险升高相关。
要点
- 早期RA达标治疗24个月,疲劳患病率由69%降至38%。
- 基线肿胀关节数少、能量多普勒评分低及PGA高预测24个月疲劳。
- 6个月未达缓解与24个月报告疲劳风险升高相关。
核心结论
- 早期RA患者疲劳在疾病初发时常见,达标治疗期间快速且持续下降。
- 基线低客观疾病活动度及高PGA是24个月临床相关疲劳的预测因素。
- 6个月未达缓解与24个月报告疲劳风险升高相关。
研究设计与样本
- 数据来自ARCTIC试验,该试验为达标治疗、严密控制的随机对照试验,评估超声在临床严密控制方案中的获益。
- 纳入基线及24个月均有疲劳数据的205例早期RA患者。
- 疲劳采用0-100 mm视觉模拟量表(VAS)测量,VAS≥20 mm定义为临床相关疲劳。
- 采用多变量逻辑回归分析24个月疲劳的基线预测因素。
主要发现
- 基线中位症状持续时间5.4个月(25th, 75th百分位数2.8, 10.4),疲劳VAS中位37.0 mm(13.0, 62.0),平均DAS 3.4(SD 1.1)。
- 疲劳患病率从基线69%降至24个月38%。
- 肿胀关节数少(OR 0.92, 95%CI 0.87至0.98, p=0.006)增加24个月临床相关疲劳风险。
- 能量多普勒超声评分低(OR 0.95, 95%CI 0.90至0.99, p=0.027)增加24个月临床相关疲劳风险。
- PGA高(OR 1.03, 95%CI 1.01至1.04, p<0.001)增加24个月临床相关疲劳风险。
临床怎么用
- 达标治疗可显著降低早期RA患者疲劳,临床应坚持达标治疗策略。
- 基线低客观疾病活动度但高PGA的患者需关注持续疲劳风险。
- 6个月未达缓解者应警惕24个月疲劳风险升高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Fatigue is a frequent symptom in rheumatoid arthritis (RA) and has high impact on quality of life. We explored associations between disease activity and fatigue in patients with early RA during the initial 24 months of modern treat-to-target therapy and predictors of fatigue after 24 months of follow-up. METHODS: Data were obtained from the treat-to-target, tight control Aiming for Remission in Rheumatoid Arthritis: a Randomised Trial Examining the Benefit of Ultrasound in a Clinical Tight Control Regime (ARCTIC) trial. Fatigue was measured on a visual analogue scale (VAS) from 0 to 100 mm and defined as clinically relevant if VAS was ≥20 mm. Baseline predictors of fatigue at 24 months were analysed by multivariable logistic regression. RESULTS: 205 patients with fatigue data at baseline and 24 months were included. Median (25th, 75th percentiles) symptom duration was 5.4 months (2.8, 10.4), fatigue VAS 37.0 mm (13.0, 62.0) and mean Disease Activity Score (DAS) 3.4 (SD 1.1) at baseline. Prevalence of fatigue declined from 69% at baseline to 38% at 24 months. Fewer swollen joints (OR 0.92, 95% CI 0.87 to 0.98, p=0.006), lower power Doppler ultrasound score (OR 0.95, 95% CI 0.90 to 0.99, p=0.027) and higher patient global assessment (PGA) (OR 1.03, 95% CI 1.01 to 1.04, p<0.001) increased the risk of clinically relevant fatigue at 24 months. Not achieving remission at 6 months was associated with a higher risk of reporting fatigue at 24 months. CONCLUSIONS: Fatigue in patients with early RA was prevalent at disease onset, with a rapid and sustained reduction during treatment. Low objective disease activity and high PGA at baseline were predictors of clinically relevant fatigue at 24 months.
引用
- Holten K, Paulshus Sundlisater N, Lillegraven S, et al. Fatigue in patients with early rheumatoid arthritis undergoing treat-to-target therapy: predictors and response to treatment. Ann Rheum Dis. 2021. PMID: 34389605. doi:10.1136/annrheumdis-2021-220750
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。